Twist Bioscience Corporation Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Twist Bioscience Corporation (TWST) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of $13.00 thousand for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-03
- Twist Bioscience Corporation effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-12-31 was $9.00K.
- Twist Bioscience Corporation effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-12-31 was -$53.00K, a 145.69% decline year-over-year.
- Twist Bioscience Corporation effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-12-31 was $116.00K, a 56.72% decline year-over-year.
- Twist Bioscience Corporation effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2022-12-31 was $268.00K, a 222.89% increase year-over-year.
- Twist Bioscience Corporation effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $143.00K, a 13.49% increase from fiscal 2024.
- Twist Bioscience Corporation effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was $126.00K.
- Twist Bioscience Corporation effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was -$27.00K.
- Twist Bioscience Corporation effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was -$319.00K, a 1695.00% decline from fiscal 2021.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.00K 10-Q · filed 2026-08-03 | |||
| 2026-03-31 | $3.00K 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | $9.00K 10-Q/A · filed 2026-02-26 | |||
| 2025-09-30 | $143.00K 10-K · filed 2025-11-17 | |||
| 2025-06-30 | -$20.00K 10-Q · filed 2026-08-03 | |||
| 2025-03-31 | $51.00K 10-Q · filed 2026-05-04 | |||
| 2024-12-31 | -$53.00K 10-Q/A · filed 2026-02-26 | |||
| 2024-09-30 | $126.00K 10-K · filed 2025-11-17 | |||
| 2024-06-30 | $53.00K 10-Q · filed 2025-08-04 | |||
| 2024-03-31 | $51.00K 10-Q · filed 2025-05-05 | |||
| 2023-12-31 | $116.00K 10-Q · filed 2025-02-03 | |||
| 2023-09-30 | -$27.00K 10-K · filed 2025-11-17 | |||
| 2023-06-30 | $21.00K 10-Q · filed 2024-08-02 | |||
| 2023-03-31 | $341.00K 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | $268.00K 10-Q · filed 2024-02-02 | |||
| 2022-09-30 | -$319.00K 10-K · filed 2024-11-18 | |||
| 2022-06-30 | -$1.00K 10-Q · filed 2023-08-07 | |||
| 2022-03-31 | $104.00K 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | $83.00K 10-Q · filed 2023-02-07 | |||
| 2021-09-30 | $20.00K 10-K · filed 2023-11-21 | |||
| 2021-06-30 | $153.00K 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | $53.00K 10-Q · filed 2022-05-06 | |||
| 2020-12-31 | $5.00K 10-Q · filed 2022-02-09 | |||
| 2020-09-30 | $21.00K 10-K/A · filed 2023-06-05 | |||
| 2020-06-30 | -$6.00K 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | -$18.00K 10-Q · filed 2021-05-07 | |||
| 2019-12-31 | $9.00K 10-Q · filed 2021-02-09 | |||
| 2019-09-30 | $30.00K 10-K · filed 2021-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |